MedTrace Logo

Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects

NCT03682172 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-02-17

No results posted yet for this study

Summary

The study will investigate the effect of the incretin hormone glucagon-like peptide 2 (GLP-2) on postprandial gallbladder motility in young, healthy, male subjects.

The study is double-blinded, randomized and placebo controlled. 15 subjects will be included. On three separate study days (A, B, C) the subjects will receive an four hour intravenous infusion with either saline (placebo), GLP-2 at a rate of 1 pmol/kg/min or GLP-2 at a rate of 10 pmol/kg/min 30 minutes after the infusion start the subject will receive a liquid meal which will stimulate gallbladder contraction.

The gallbladder volume will be determined by frequent ultrasonic scans, and blood samples will be drawn on fixed times through out the study day.

Conditions

  • Effect of Glucagon-like Peptide 2 on Gallbladder Motility

Interventions

DRUG

GLP-2 (1pmol/kg/min)

Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min

DRUG

GLP-2 (10pmol/kg/min)

Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min

DRUG

Placebo

Four hour intravenous infusion with saline water

Sponsors & Collaborators

  • Steno Diabetes Center Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, phd · Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2018-08-30
Completion
2020-07-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03682172 on ClinicalTrials.gov